We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
+27.21%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$994K
AUM Growth
-$358M
Cap. Flow
+$7.47M
Cap. Flow %
751.58%
Top 10 Hldgs %
86.65%
Holding
46
New
10
Increased
4
Reduced
16
Closed
3

Top Buys

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$47.8M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$7.13M
3
KRON
Kronos Bio
KRON
+$5.22M
4
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$3.22M
5
CHFW.U
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
+$3.06M

Top Sells

Rank Stock Value
1
CVAC
CureVac
CVAC
+$21.1M
2
COGT icon
Cogent Biosciences
COGT
+$9.14M
3
SWTX
SpringWorks Therapeutics
SWTX
+$8.72M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.39M
5
ALLK
Allakos
ALLK
+$4.8M

Sector Composition

Rank Sector Weight
1 Financials 51.32%
2 Healthcare 47.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
26
Rocket Pharmaceuticals
RCKT
$394M
$3.5K 0.35%
63,770
-35,873
-36% -$1.31M
FULC icon
27
Fulcrum Therapeutics
FULC
$297M
$3.44K 0.35%
294,118
– –
NVAX icon
28
Novavax
NVAX
$1.31B
$3.36K 0.34%
30,160
+8,500
+39% +$903K
BLSA
29
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$3.34K 0.34%
+300,000
New +$3.22M
VTGN icon
30
VistaGen Therapeutics
VTGN
$12.8M
$3.18K 0.32%
+54,679
New +$1.4M
KLRS
31
Kalaris Therapeutics
KLRS
$96.8M
$3.17K 0.32%
3,580
-379
-10% -$292K
CHFW.U
32
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$3.14K 0.32%
+300,000
New +$3.06M
AVDL
33
DELISTED
Avadel Pharmaceuticals
AVDL
$2.9K 0.29%
+434,250
New +$2.72M
SNCE
34
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$2.13K 0.21%
+10,000
New +$2.08M
GERN icon
35
Geron
GERN
$949M
$1.95K 0.2%
1,224,870
-306,218
-20% -$558K
HOOK
36
DELISTED
HOOKIPA Pharma
HOOK
$1.44K 0.14%
12,966
+1,306
+11% +$141K
KALV
37
DELISTED
KalVista Pharmaceuticals
KALV
$1.28K 0.13%
67,270
-16,817
-20% -$288K
SPRY icon
38
ARS Pharmaceuticals
SPRY
$612M
$1.16K 0.12%
+25,000
New +$835K
BNTX icon
39
BioNTech
BNTX
$23.5B
$880 0.09%
10,795
-1,905
-15% -$187K
KDMN
40
DELISTED
Kadmon Holdings, Inc.
KDMN
$685 0.07%
+165,000
New +$651K
ATXS
41
DELISTED
Astria Therapeutics
ATXS
$642 0.06%
50,000
– –
NGM
42
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$552 0.06%
18,225
-18,226
-50% -$399K
AMRN
43
Amarin Corp
AMRN
$303M
$122 0.01%
1,250
– –
SPRO icon
44
Spero Therapeutics
SPRO
$73M
– –
-160,000
Closed -$1.79M
UROV
45
DELISTED
Urovant Sciences Ltd.
UROV
– –
-157,480
Closed -$1.47M
AIMT
46
DELISTED
Aimmune Therapeutics
AIMT
– –
-58,142
Closed -$2M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q4 2020 Portfolio in Review

As of Q4 2020, Samsara BioCapital held 46 positions worth $994K, down 100% from $359M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Samsara BioCapital deployed $7.47M of net new capital in Q4 2020, opening 10 new positions and adding to 4 existing holdings. Its largest new stake was Chinook Therapeutics, Inc. Common Stock: 3,168,388 shares worth $50.3K.

By sector, the portfolio is most concentrated in Financials at 51% of assets, followed by Healthcare.

On the sell side, the largest reduction was CureVac, an estimated $21.1M trimmed.

  • Samsara BioCapital's largest Q4 2020 buy was Chinook Therapeutics, Inc. Common Stock: 3,168,388 shares worth $50.3K.
  • Samsara BioCapital added most to Syros Pharmaceuticals, Inc. Common Stock in Q4 2020, an estimated $7.13M increase.
  • Samsara BioCapital's biggest Q4 2020 reduction was CureVac, cutting an estimated $21.1M.
  • Samsara BioCapital fully exited Aimmune Therapeutics in Q4 2020, selling an estimated $2M.
  • Samsara BioCapital's ten largest holdings make up 87% of its $994K portfolio in Q4 2020.
  • Samsara BioCapital opened 10 new positions and closed 3 in Q4 2020.
  • Samsara BioCapital's portfolio value fell 100% quarter-over-quarter to $994K.

Based on Samsara BioCapital's 13F filing for Q4 2020, filed 17 Feb 2021.